구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ADV-TK (ADV-TK, adenovirus-thymidine kinase enzyme, ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy) Candel Therapeutics, Inc.·Hepatocellular Carcinoma 1 trials |
|---|---|
Overview Program | ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy |
Overview Company | Candel Therapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Hepatocellular Carcinoma; Liver Transplantation |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.. Gene-mediated cytotoxic immunotherapy (GMCI) is an immune strategy implemented through local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir. A phase I dose escalation trial of… |
Toxicology CRS | grade 2 |
Clinical Safety signal | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.. Gene-mediated cytotoxic immunotherapy (GMCI) is an immune strategy implemented through local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir. A phase I dose escalation trial of… |
Clinical Selected reported efficacy | ORR 11% |
Clinical Reported ORR | 11% |
Clinical Result source | ClinicalTrials.gov NCT02831933 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02831933 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ADV-TK (ADV-TK, adenovirus-thymidine kinase enzyme, ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy) Candel Therapeutics, Inc.·Hepatocellular Carcinoma 1 trials |
|---|---|
Overview Program | ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy |
Overview Company | Candel Therapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Hepatocellular Carcinoma; Liver Transplantation |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.. Gene-mediated cytotoxic immunotherapy (GMCI) is an immune strategy implemented through local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir. A phase I dose escalation trial of… |
Toxicology CRS | grade 2 |
Clinical Safety signal | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.. Gene-mediated cytotoxic immunotherapy (GMCI) is an immune strategy implemented through local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir. A phase I dose escalation trial of… |
Clinical Selected reported efficacy | ORR 11% |
Clinical Reported ORR | 11% |
Clinical Result source | ClinicalTrials.gov NCT02831933 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02831933 |
추천 비교
추천 비교